trending Market Intelligence /marketintelligence/en/news-insights/trending/qqhgwknt1mpc4ayuwkqyza2 content esgSubNav
In This List

Prometic gastrointestinal disease drug gets US FDA orphan drug designation

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Prometic gastrointestinal disease drug gets US FDA orphan drug designation

The U.S. Food and Drug Administration granted orphan drug designation to ProMetic Life Sciences Inc.'s inter-alpha-inhibitor-proteins for treating necrotizing enterocolitis.

Necrotizing enterocolitis is the most common acquired gastrointestinal disease affecting premature infants. It is characterized by damage to the intestinal wall, leading to perforation of the intestine and spilled stool into the infant's abdomen.